By Christopher Piercecchi, MD
Physician and Wellness Manager, Founder, The Men’s Clinic for Wellness & Vitality
This week, the FDA’s Pharmacy Compounding Advisory Committee recommended adding six experimental peptides to the federal list of bulk substances that traditional compounding pharmacies may use. The list included BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon.
Peptide clinics and companies that profit from selling these products are already celebrating the decision and describing the substances as having been “cleared.” That language is misleading.
The FDA did not approve any of these peptides. It did not determine that they are safe. It did not determine that they work. It did not approve an indication, dosage, route of administration, manufacturing process, or product label. The committee’s vote was advisory and nonbinding, and nothing automatically changed at the pharmacy counter when the votes were counted.
What Actually Happened
What the committee considered was whether these substances should eventually be placed on the 503A Bulk List. That is a legal pathway allowing a compounding pharmacy to prepare an unapproved medication from a bulk ingredient for an identified patient with a prescription. It is not the process used to approve a new drug, which normally requires controlled human trials demonstrating safety, effectiveness, and an acceptable balance between benefits and risks.
Traditional compounding exemptions serve a legitimate purpose. A patient may need a special concentration, a liquid instead of a tablet, or a formulation without a particular inactive ingredient. Using that same pathway to manufacture injectable experimental compounds that have never been approved for human use is a very different proposition. It allows an unapproved drug to enter clinical practice without undergoing the evidentiary process we ordinarily require before injecting something into patients.
The FDA’s own scientific staff recommended against adding all seven substances reviewed. Their concerns included inadequate human evidence, uncertain effectiveness, limited safety data, possible immune reactions, peptide-related impurities and questions about product characterization and manufacturing consistency.
Despite those concerns, the committee voted in favor of six of them.
The Political Context
It is also difficult to ignore the political context. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly promoted peptides and has made his hostility toward the traditional medical and regulatory establishment well known. Several people with professional or commercial connections to peptide clinics, pharmacies or related businesses were added to the advisory committee before the meeting.
That does not prove that anyone was instructed how to vote. It does, however, raise reasonable questions about whether political ideology, personal enthusiasm and commercial pressure are beginning to outrun scientific judgment.
What This Means for You
Patients need to understand exactly what this decision means. It may eventually make these products easier for compounding pharmacies and clinics to sell. It does not make them FDA-approved medications, and it does not suddenly create the missing clinical evidence.
A physician may eventually be legally permitted to prescribe one through a compounding pathway. That does not necessarily make the prescription medically responsible. Legal availability and evidence-based medicine are not the same thing.
For those of you who want my full take on peptides: there is no clear safety record for these compounds, and there is no indication for any of them to be prescribed for any meaningful medical purpose. I have written about this at length before. If you want the deeper dive, refer to my prior SITREP here: The Truth About Peptides.
The SITREP Bottom Line
The science did not change this week. No major clinical trials were completed, no new safety data appeared and none of these peptides received FDA approval. An advisory committee simply voted to lower a regulatory barrier.
Until credible human trials establish appropriate dosing, meaningful clinical benefits and acceptable safety, these peptides remain experimental products surrounded by far more marketing than medicine.
Medical Disclaimer
The Men’s Health SITREP is for general educational and informational purposes only. It reviews and interprets published research. It does not constitute medical advice and does not create a physician-patient relationship.
Nothing here is a substitute for individualized care from your own physician, who knows your history, your laboratory results and your circumstances. Do not start, stop or change any medication or treatment based on what you read here.
Back to All Blogs